Associations Of TLR9 Rs352140 Polymorphisms With Myasthenia Gravis

Objective To determine the associations between TLR9 rs352140 polymorphism and myasthenia gravis (MG).Methods TLR9 rs352140 polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The frequencies of genotype and alleles were compared among different subgroups. The relationship between the genotype and severity of MG and short-term efficiency of glucocorticoid were also explored.Results There were no significant differences in frequencies of genotypes and alleles between MG group and control group, and among subgroups of MG (P>0.05). In those with worse short-term efficiency of glucocorticoid, generalized MG patients were more prevalent than ocular MG patients (P=0.03, OR=3.592), and patients with thymoma were more prevalent than patients without thymoma (P=0.016, OR=4.350); the mean pretreatment MGFA score was higher in patients with worse efficiency of glucocorticoid (P=0.026). Logistic regression analysis found that the higher MGFA score, the worse efficiency of glucocorticoid was in MG patients (P=0.043, OR=1.154).Conclusions There was not significant correlation between TLR9 rs352140 polymorphism and MG susceptibility and glucocorticoid efficiency.